These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 35210989)

  • 41. Astroglial tracer BU99008 detects multiple binding sites in Alzheimer's disease brain.
    Kumar A; Koistinen NA; Malarte ML; Nennesmo I; Ingelsson M; Ghetti B; Lemoine L; Nordberg A
    Mol Psychiatry; 2021 Oct; 26(10):5833-5847. PubMed ID: 33888872
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD transgenic rat model of AD: a collaborative multi-modal study.
    Chaney AM; Lopez-Picon FR; Serrière S; Wang R; Bochicchio D; Webb SD; Vandesquille M; Harte MK; Georgiadou C; Lawrence C; Busson J; Vercouillie J; Tauber C; Buron F; Routier S; Reekie T; Snellman A; Kassiou M; Rokka J; Davies KE; Rinne JO; Salih DA; Edwards FA; Orton LD; Williams SR; Chalon S; Boutin H
    Theranostics; 2021; 11(14):6644-6667. PubMed ID: 34093845
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Monoamine oxidase B inhibitor, selegiline, reduces
    Ng KP; Pascoal TA; Mathotaarachchi S; Therriault J; Kang MS; Shin M; Guiot MC; Guo Q; Harada R; Comley RA; Massarweh G; Soucy JP; Okamura N; Gauthier S; Rosa-Neto P
    Alzheimers Res Ther; 2017 Mar; 9(1):25. PubMed ID: 28359327
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer's Disease and Other Tauopathies.
    Maschio C; Ni R
    Front Aging Neurosci; 2022; 14():838034. PubMed ID: 35527737
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development and Clinical Application of Positron Emission Tomography Imaging Agents for Monoamine Oxidase B.
    Meyer JH; Braga J
    Front Neurosci; 2021; 15():773404. PubMed ID: 35280341
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders.
    Maeda J; Zhang MR; Okauchi T; Ji B; Ono M; Hattori S; Kumata K; Iwata N; Saido TC; Trojanowski JQ; Lee VM; Staufenbiel M; Tomiyama T; Mori H; Fukumura T; Suhara T; Higuchi M
    J Neurosci; 2011 Mar; 31(12):4720-30. PubMed ID: 21430171
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer's Disease.
    Borroni E; Bohrmann B; Grueninger F; Prinssen E; Nave S; Loetscher H; Chinta SJ; Rajagopalan S; Rane A; Siddiqui A; Ellenbroek B; Messer J; Pähler A; Andersen JK; Wyler R; Cesura AM
    J Pharmacol Exp Ther; 2017 Sep; 362(3):413-423. PubMed ID: 28642233
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases.
    Vermeiren C; Motte P; Viot D; Mairet-Coello G; Courade JP; Citron M; Mercier J; Hannestad J; Gillard M
    Mov Disord; 2018 Feb; 33(2):273-281. PubMed ID: 29278274
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of AV-1451 as a Weak, Nonselective Inhibitor of Monoamine Oxidase.
    Drake LR; Pham JM; Desmond TJ; Mossine AV; Lee SJ; Kilbourn MR; Koeppe RA; Brooks AF; Scott PJH
    ACS Chem Neurosci; 2019 Aug; 10(8):3839-3846. PubMed ID: 31339297
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Candidate PET Radioligand Development for Neurofibrillary Tangles: Two Distinct Radioligand Binding Sites Identified in Postmortem Alzheimer's Disease Brain.
    Cai L; Qu B; Hurtle BT; Dadiboyena S; Diaz-Arrastia R; Pike VW
    ACS Chem Neurosci; 2016 Jul; 7(7):897-911. PubMed ID: 27171905
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias.
    Wren MC; Lashley T; Årstad E; Sander K
    Acta Neuropathol Commun; 2018 May; 6(1):34. PubMed ID: 29716656
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tau accumulation in astrocytes in progressive supranuclear palsy is a degenerative rather than a reactive process.
    Togo T; Dickson DW
    Acta Neuropathol; 2002 Oct; 104(4):398-402. PubMed ID: 12200627
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of monoamine oxidase B prevents reactive astrogliosis and scar formation in stab wound injury model.
    Chun H; Lim J; Park KD; Lee CJ
    Glia; 2022 Feb; 70(2):354-367. PubMed ID: 34713936
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimer's Brain Tissue.
    Ni R; Röjdner J; Voytenko L; Dyrks T; Thiele A; Marutle A; Nordberg A
    J Alzheimers Dis; 2021; 80(4):1723-1737. PubMed ID: 33749648
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The difference in gliosis induced by β-amyloid and Tau treatments in astrocyte cultures derived from senescence accelerated and normal mouse strains.
    Lü L; Mak YT; Fang M; Yew DT
    Biogerontology; 2009 Dec; 10(6):695-710. PubMed ID: 19221889
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Longitudinal Assessment of Tau-Associated Pathology by
    Moreno-Gonzalez I; Edwards GA; Hasan O; Gamez N; Schulz JE; Fernandez-Valenzuela JJ; Gutierrez A; Soto C; Schulz PE
    Diagnostics (Basel); 2021 Oct; 11(10):. PubMed ID: 34679572
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical Evaluation of 18F-PI-2620 as a Potent PET Radiotracer Imaging Tau Protein in Alzheimer Disease and Other Neurodegenerative Diseases Compared With 18F-THK-5351.
    Oh M; Oh SJ; Lee SJ; Oh JS; Roh JH; Chung SJ; Lee JH; Lee CS; Kim JS
    Clin Nucl Med; 2020 Nov; 45(11):841-847. PubMed ID: 32910050
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
    Watanabe H
    Yakugaku Zasshi; 2017; 137(11):1361-1365. PubMed ID: 29093372
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preclinical Evaluation of
    Honer M; Gobbi L; Knust H; Kuwabara H; Muri D; Koerner M; Valentine H; Dannals RF; Wong DF; Borroni E
    J Nucl Med; 2018 Apr; 59(4):675-681. PubMed ID: 28970331
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [
    Oh M; Oh JS; Oh SJ; Lee SJ; Roh JH; Kim WR; Seo HE; Kang JM; Seo SW; Lee JH; Na DL; Noh Y; Kim JS
    J Clin Neurol; 2022 Jul; 18(4):437-446. PubMed ID: 35796269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.